Edition:
India

People: Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

50.71USD
27 May 2020
Change (% chg)

$-4.22 (-7.68%)
Prev Close
$54.93
Open
$55.44
Day's High
$55.44
Day's Low
$50.48
Volume
57,883
Avg. Vol
96,382
52-wk High
$100.55
52-wk Low
$38.41

Mellett, Paul 

Mr. Paul J. Mellett Jr. serves as Chief Financial Officer, Senior Vice President - Finance & Administration of the Company. From April 2001 through August 2003, he held the position of Senior Vice President and Chief Financial Officer of Essential Therapeutics, Inc., a publicly-held biotechnology company. Previously, Mr. Mellett was the Chief Financial Officer and Vice President of Administration at GelTex Pharmaceuticals, Inc., a publicly held biotechnology company that was acquired by Genzyme Corporation in December 2000. From 1994 to 1997, Mr. Mellett served as Chief Financial Officer of Marshall Contractors, a construction management firm specializing in the pharmaceutical, biotechnology and semiconductor industries, which was acquired by Fluor Corporation in 1996. From 1977 to 1994, Mr. Mellett was employed with Deloitte & Touche LLP, a public accounting firm, and was promoted to Audit Partner in 1989. Mr. Mellett received a B.S. in Business Administration from Boston College in 1977.

Basic Compensation

Total Annual Compensation, USD 411,775
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,119,790
Fiscal Year Total, USD 1,531,560

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 6,960 657,313.00
Name Fiscal Year Total

Bruce Carter

351,580

Jay Luly

4,483,500

Paul Mellett

1,531,560

Yat Sun Or

1,630,810

Nathaniel Gardiner

1,494,230

Nathalie Adda

1,614,800
As Of  30 Sep 2019